A hospital can approve an AI tool and still lose track of what it is using. A vendor releases an update, a team expands the workflow, or the original clinical owner moves on. The review remains on file; the conditions behind it may have changed.
That is the useful question raised by CHAI's latest governance spotlight. Health systems need a way to connect the purchasing decision with subsequent use, changes and incidents. The operational challenge deserves attention on its own terms.
In this deep dive, we are going to look at:
- Why this matters now
- What actually happened
- The obvious read versus the deeper signal
- Taxonomy: Three different kinds of assurance
- From initial review to a living governance record
- Capital flows, incentives, and bottom-up economics
- The HealthTech Investor's Signal, the counter-thesis and four observable indicators
Why this matters now
Oversight becomes harder as AI reaches organizations through multiple routes: purchased applications, internally developed systems and features added to existing software. A committee cannot assess what it does not know has entered the workflow.
Start with a working inventory. For each use, identify the owner, intended population, role in the decision and version in service. Those fields make later review possible. They also help distinguish an administrative feature from a tool that could materially affect a clinical decision.
What actually happened
On October 15, CHAI published a governance conversation with Hartford HealthCare's Rocco Orlando, its Strategic Advisor and Emeritus Chief Academic Officer. It described oversight extending beyond intake, including awareness of vendor changes and ongoing review. This is an organizational account, rather than an independent comparative study.
Earlier this month, CHAI released a draft intake playbook and accompanying controls workbook for piloting. The document describes a voluntary approach to organizing review. Separately, the Joint Commission launched its voluntary Responsible Use of AI in Healthcare certification on June 1. These developments do not establish a new federal device-approval route.
The obvious read versus the deeper signal
The obvious interpretation is demand for more documentation. Our deeper read is demand for institutional memory: a record that explains which use was accepted, on what evidence and subject to which conditions.
A well-organized record can make the next decision easier. It lets a reviewer compare an update with the original use and identify the evidence that may need refreshing. This practical value does not depend on claiming that a private framework replaces public regulation.
